Comparative Pharmacology
Head-to-head clinical analysis: NADOLOL versus TRANDATE.
Head-to-head clinical analysis: NADOLOL versus TRANDATE.
NADOLOL vs TRANDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective beta-adrenergic receptor antagonist (beta-blocker) that competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
Competitive antagonist at beta-1 and beta-2 adrenergic receptors; also blocks alpha-1 adrenergic receptors, causing vasodilation.
40 to 80 mg orally once daily, may be increased at 3-7 day intervals up to 240 mg once daily.
Initial: 100 mg orally twice daily, titrate to 200-400 mg twice daily; maximum 2400 mg/day. Alternatively, 20 mg IV bolus over 2 minutes, then 40-80 mg IV at 10-minute intervals as needed; IV infusion: 2 mg/min, titrate to response.
None Documented
None Documented
Clinical Note
moderateNadolol + Digitoxin
"Nadolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateNadolol + Deslanoside
"Nadolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateNadolol + Acetyldigitoxin
"Nadolol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateNadolol + Ouabain
"Nadolol may increase the bradycardic activities of Ouabain."
Terminal elimination half-life: 14–24 hours (average 20 hours); prolonged in renal impairment (up to 45 hours) allowing once-daily dosing
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged in patients with hepatic impairment or severe renal dysfunction (up to 12-16 hours).
Renal (unchanged drug) 75-85%; fecal/biliary <5%
Labetalol is extensively metabolized in the liver via glucuronidation; less than 5% of the dose is excreted unchanged in urine. Approximately 55-60% of metabolites are excreted renally, and about 30% in feces via biliary secretion.
Category C
Category C
Beta-Blocker
Beta-Blocker